/ /

Keith Loria
Keith Loria is a contributing writer to Medical Economics.
Aerobic exercise boosts testosterone levels
Overweight and obese men who participated in 12 weeks of aerobic exercise saw significantly increased testosterone levels, a recent study found.
Persistent decline in renal function seen after first stone case
“Our research shows that the implications of kidney stones may go beyond the discomfort they are so often associated with,” says co-lead author Andrew Rule, MD.
Is 1.5 the new magic number for PSA screening?
A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.
Why aren’t more doctors using patient engagement tools?
Why aren’t more doctors using patient engagement tools?
A new report reveals that 69% of healthcare providers are using patient engagement to get patients more involved in their own care, but its authors suggest that number should be closer to 100%.
Upbringing, socioeconomic status linked to PCa
A recent study shows children born to high-status parents have a higher incidence rate of developing prostate and other cancers in later life.
Has ordering of PSA screening dropped among PCPs?
An examination of data involving more than 63,000 PSA tests ordered by primary care physicians reveals some surprising findings.
Researchers validate robotic cystectomy quality tool
A team from Roswell Park Cancer Institute has developed and validated a quality assessment tool based on prospectively collected data on robot-assisted cystectomy.
Physician’s political party could affect healthcare, study finds
Physician’s political party could affect healthcare, study finds
The care you receive from your doctor could depend on whether he or she is a Democrat or Republican
Testosterone solution yields improved sex drive, energy
A new study finds that treatment with testosterone solution 2% can be effective for hypogonadism with no new safety concerns.
SBRT yields excellent Ca control, low rate of severe toxicity
Results from a multicenter study show progression-free survival in 97% of low- and intermediate-risk prostate cancer patients.